PDS Biotech Pauses Recruitment In PDS0101 Combo Cancer Trial

PDS Biotechnology Corporation PDSB has temporarily suspended recruitment in the National Cancer Institute (NCI)-led Phase 2 trial of PDS0101 combo trial in advanced HPV cancers
The issue is not specific to the PDS0101 trial and is unrelated to the triple combination's safety or efficacy concerns.
The NCI anticipates that the issue should be resolved timely.
The trial is evaluating the novel combination in both checkpoint inhibitor naïve and refractory patients with advanced HPV-associated cancers that have progressed or returned after treatment.
PDS Biotech's lead candidate, PDS0101, combines the Versamune platform with targeted antigens in HPV-expressing cancers.
In partnership with Merck & Co Inc MRK, PDS Biotech is evaluating PDS0101 combined with Keytruda in a Phase 2 study in head and neck cancer.
PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.
Price Action: PDSB shares are down 4.07% at $11.56 during the premarket session on the last check Thursday.